Oxford Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Oxford Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$284K	Buy	+80,776	New	+$258K	0.12%	261
2019 Q2	–	Sell	-23,859	Closed	-$227K	–	1837
2019 Q1	$227K	Sell	23,859 -87,613	-79%	-$851K	﹤0.01%	1483
2018 Q4	$987K	Buy	+111,472	New	+$1.08M	0.03%	875
2018 Q3	–	Sell	-85,065	Closed	-$1.11M	–	1803
2018 Q2	$1.11M	Sell	85,065 -45,873	-35%	-$670K	0.02%	982
2018 Q1	$2.21M	Sell	130,938 -27,560	-17%	-$417K	0.05%	518
2017 Q4	$1.28M	Buy	+158,498	New	+$1.27M	0.03%	814
2017 Q2	–	Sell	-39,926	Closed	-$297K	–	1582
2017 Q1	$297K	Sell	39,926 -60,256	-60%	-$442K	0.01%	1205
2016 Q4	$696K	Sell	100,182 -227,251	-69%	-$1.56M	0.02%	538
2016 Q3	$2.69M	Sell	327,433 -81,626	-20%	-$690K	0.08%	337
2016 Q2	$3.31M	Sell	409,059 -195,328	-32%	-$1.23M	0.11%	249
2016 Q1	$3.07M	Buy	604,387 +326,203	+117%	+$1.79M	0.09%	283
2015 Q4	$2.15M	Buy	+278,184	New	+$1.93M	0.05%	384

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Oxford Asset Management's IOVA Position: Q1 2026 in Review

Oxford Asset Management opened a new position in Iovance Biotherapeutics (IOVA) in Q1 2026: 80,776 shares worth $284K. The stake represents 0.12% of the portfolio and ranks #261 among its holdings. This is a return to the name: Oxford Asset Management previously reported a position in IOVA as recently as Q1 2019.

Oxford Asset Management first reported a position in IOVA in Q4 2015 and has held it in 12 quarters since. The position peaked at $3.31M in Q2 2016. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Oxford Asset Management held 80,776 shares of Iovance Biotherapeutics worth $284K as of Q1 2026.
Iovance Biotherapeutics was a new Oxford Asset Management position in Q1 2026.
Iovance Biotherapeutics made up 0.12% of Oxford Asset Management's portfolio in Q1 2026, its #261 holding.
Oxford Asset Management first reported a position in Iovance Biotherapeutics in Q4 2015 and has held it in 12 quarters since.
Oxford Asset Management's Iovance Biotherapeutics position peaked at $3.31M in Q2 2016.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.